Related Experiment Video

Updated: Jun 25, 2026

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice

Wan C Tsai1, Marc B Hershenson, Ying Zhou

  • 1Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI 48105, USA.

Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|March 10, 2009
PubMed
Abstract

Insights

Azithromycin (AZM) treatment improved survival in cystic fibrosis (CF) mice infected with Pseudomonas aeruginosa (PA). AZM reduced bacterial load and lung inflammation by enhancing immune defenses.

Area of Science:

  • Pulmonary Medicine
  • Microbiology
  • Immunology

Background:

  • Cystic Fibrosis (CF) is characterized by chronic Pseudomonas aeruginosa (PA) infection and inflammation.
  • Azithromycin (AZM) is used for its anti-inflammatory effects in CF patients with PA infection.

Purpose of the Study:

  • To investigate the mechanisms behind AZM's beneficial effects in CF.
  • To assess AZM's impact on bacterial load, cytokine levels, and inflammatory cell clearance in a CF mouse model.

Main Methods:

  • CF mice infected with mucoid PA were treated with AZM or saline.
  • Evaluated survival, lung bacterial load, inflammation, cytokine levels (IFN-gamma), and apoptotic cells.

Main Results:

  • AZM treatment significantly increased 5-day survival (95% vs. 56% with saline).
  • AZM reduced bacterial load, lung inflammation, and increased IFN-gamma levels.
  • AZM enhanced macrophage clearance of apoptotic neutrophils.

Conclusions:

  • Azithromycin enhances bacterial clearance in CF mice.
  • AZM reduces lung inflammation by improving innate immune defenses.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: